|
🦁
|
Significant clinical benefit of first‐line palliative chemotherapy in advanced soft‐tissue sarcoma
V. Karavasilis,
B. Seddon,
S. Ashley,
O. Al-Muderis,
C. Fisher,
I. Judson
|
7 |
2008 |
7
🦁
|
|
🐜
|
Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).
13 auth.
L. R. Molife,
G. Attard,
P. Fong,
V. Karavasilis,
A. Reid,
S. Patterson,
C. Riggs,
C. Higano,
W. Stadler,
W. McCulloch,
...
D. Dearnaley,
C. Parker,
J. Bono
|
7 |
2010 |
7
🐜
|
|
🐜
|
Phase I Pharmacokinetic and Pharmacodynamic Study of LAQ824, a Hydroxamate Histone Deacetylase Inhibitor with a Heat Shock Protein-90 Inhibitory Profile, in Patients with Advanced Solid Tumors
15 auth.
J. D. de Bono,
R. Kristeleit,
A. Tolcher,
P. Fong,
S. Pacey,
V. Karavasilis,
M. Mita,
H. Shaw,
P. Workman,
S. Kaye,
...
E. Rowinsky,
W. Aherne,
P. Atadja,
J. Scott,
A. Patnaik
|
6 |
2008 |
6
🐜
|
|
🐬
|
Novel therapeutic approaches in chondrosarcoma.
Genovefa Polychronidou,
V. Karavasilis,
S. Pollack,
Paul H. Huang,
Alexander Lee,
Robin L. Jones
|
6 |
2017 |
6
🐬
|
|
🐜
|
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
18 auth.
L. R. Molife,
P. Fong,
L. Paccagnella,
A. Reid,
H. Shaw,
L. Vidal,
H. Arkenau,
V. Karavasilis,
T. Yap,
D. Olmos,
...
J. Spicer,
S. Postel-Vinay,
D. Yin,
A. Lipton,
L. Demers,
K. Leitzel,
A. Gualberto,
J. Bono
|
6 |
2010 |
6
🐜
|
|
🐜
|
90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?
9 auth.
H. Arkenau,
D. Olmos,
J. Ang,
J. Barriuso,
V. Karavasilis,
S. Ashley,
...
J. D. de Bono,
I. Judson,
S. Kaye
|
5 |
2008 |
5
🐜
|
|
🐜
|
Immunohistochemical expression of superoxide dismutase (MnSOD) anti-oxidant enzyme in invasive breast carcinoma.
8 auth.
E. Tsanou,
E. Ioachim,
E. Briasoulis,
K. Damala,
A. Charchanti,
V. Karavasilis,
...
N. Pavlidis,
N. Agnantis
|
5 |
2004 |
5
🐜
|
|
🐜
|
Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
17 auth.
D. Pectasides,
V. Karavasilis,
G. Papaxoinis,
G. Gourgioti,
T. Makatsoris,
G. Raptou,
E. Vrettou,
J. Sgouros,
E. Samantas,
G. Basdanis,
...
P. Papakostas,
D. Bafaloukos,
V. Kotoula,
H. Kalofonos,
C. Scopa,
G. Pentheroudakis,
G. Fountzilas
|
5 |
2015 |
5
🐜
|
|
🐜
|
Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration.
8 auth.
E. Briasoulis,
V. Karavasilis,
D. Anastasopoulos,
E. Tzamakou,
G. Fountzilas,
D. Rammou,
...
V. Kostadima,
N. Pavlidis
|
5 |
1999 |
5
🐜
|
